Is adjuvant tamoxifen recommended in post-menopausal node-negative breast cancer patients with high estrogen receptor values?

Abstract

The impact of ER levels on the response to tamoxifen was evaluated in 1623 postmenopausal primary breast cancer patients treated at our center (median follow-up 8.2 years). In patients receiving adjuvant tamoxifen a significantly longer disease-free survival (DFS) was observed when ER levels were elevated (p < 0.00001). Very high ER (> 424 fmol/mg protein) appeared to be detrimental in node-negative patients not treated with tamoxifen.